Katherine A Lyseng-Williamson

Summary

Affiliation: Adis International Limited
Country: New Zealand

Publications

  1. ncbi request reprint Tramadol/paracetamol
    Karen McClellan
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 63:1079-86; discussion 1087-8. 2003
  2. ncbi request reprint Latanoprost : an update of its use in glaucoma and ocular hypertension
    Caroline M Perry
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs Aging 20:597-630. 2003
  3. ncbi request reprint Retigabine: in partial seizures
    Greg L Plosker
    Adis International Limited, Auckland, New Zealand
    CNS Drugs 20:601-8; discussion 609-10. 2006
  4. pmc Niacin extended release (ER)/simvastatin (Simcor®): a guide to its use in lipid regulation
    Katherine A Lyseng-Williamson
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs R D 10:253-60. 2010
  5. doi request reprint Etravirine: a review of its use in the management of treatment-experienced patients with HIV-1 infection
    Jamie D Croxtall
    Adis, Auckland, New Zealand
    Drugs 72:847-69. 2012
  6. doi request reprint Acetylsalicylic acid/esomeprazole fixed-dose combination
    Celeste B Burness
    Adis, Auckland, New Zealand
    Drugs Aging 29:233-42. 2012
  7. doi request reprint Tapentadol extended release: in adults with chronic pain
    Sheridan M Hoy
    Adis, Auckland, New Zealand
    Drugs 72:375-93. 2012
  8. ncbi request reprint Anidulafungin
    David Murdoch
    Adis International Limited, Auckland, New Zealand
    Drugs 64:2249-58; discussion 2259-60. 2004
  9. doi request reprint Efalizumab: a review of its use in the management of chronic moderate-to-severe plaque psoriasis
    James E Frampton
    Wolters Kluwer Health Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand
    Am J Clin Dermatol 10:51-72. 2009
  10. doi request reprint Losartan/Hydrochlorothiazide: a review of its use in the treatment of hypertension and for stroke risk reduction in patients with hypertension and left ventricular hypertrophy
    Gillian M Keating
    Wolters Kluwer Health, Adis, Auckland, New Zealand
    Drugs 69:1239-65. 2009

Collaborators

Detail Information

Publications485 found, 100 shown here

  1. ncbi request reprint Tramadol/paracetamol
    Karen McClellan
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 63:1079-86; discussion 1087-8. 2003
    ..5/325 mg provided similar efficacy to that of codeine/paracetamol 30/300 mg in patients with chronic back pain in a 4-week, randomised, double-blind trial (a maximum of 10 tablets or capsules per day of the active drug)...
  2. ncbi request reprint Latanoprost : an update of its use in glaucoma and ocular hypertension
    Caroline M Perry
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs Aging 20:597-630. 2003
    ..Although preliminary findings are promising, wider clinical experience is required to define the place of latanoprost in the treatment of angle-closure glaucoma...
  3. ncbi request reprint Retigabine: in partial seizures
    Greg L Plosker
    Adis International Limited, Auckland, New Zealand
    CNS Drugs 20:601-8; discussion 609-10. 2006
    ..Across all three retigabine groups in the large phase II trial, somnolence (20.3%), dizziness (14.6%), confusion (12.3%) and speech disorder (11.3%) were the most frequent CNS-related adverse events...
  4. pmc Niacin extended release (ER)/simvastatin (Simcor®): a guide to its use in lipid regulation
    Katherine A Lyseng-Williamson
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs R D 10:253-60. 2010
    ....
  5. doi request reprint Etravirine: a review of its use in the management of treatment-experienced patients with HIV-1 infection
    Jamie D Croxtall
    Adis, Auckland, New Zealand
    Drugs 72:847-69. 2012
    ....
  6. doi request reprint Acetylsalicylic acid/esomeprazole fixed-dose combination
    Celeste B Burness
    Adis, Auckland, New Zealand
    Drugs Aging 29:233-42. 2012
    ..Low-dose ASA plus esomeprazole treatment was generally well tolerated, with a similar adverse event profile to that seen with low-dose ASA plus placebo...
  7. doi request reprint Tapentadol extended release: in adults with chronic pain
    Sheridan M Hoy
    Adis, Auckland, New Zealand
    Drugs 72:375-93. 2012
    ..Oral tapentadol ER therapy for up to 24 months was generally well tolerated, with the nature of treatment-emergent adverse events generally similar across the clinical studies...
  8. ncbi request reprint Anidulafungin
    David Murdoch
    Adis International Limited, Auckland, New Zealand
    Drugs 64:2249-58; discussion 2259-60. 2004
    ..In the largest clinical trial to date, the most common treatment-related adverse events were phlebitis/thrombophlebitis, headache, nausea, vomiting and pyrexia...
  9. doi request reprint Efalizumab: a review of its use in the management of chronic moderate-to-severe plaque psoriasis
    James E Frampton
    Wolters Kluwer Health Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand
    Am J Clin Dermatol 10:51-72. 2009
    ....
  10. doi request reprint Losartan/Hydrochlorothiazide: a review of its use in the treatment of hypertension and for stroke risk reduction in patients with hypertension and left ventricular hypertrophy
    Gillian M Keating
    Wolters Kluwer Health, Adis, Auckland, New Zealand
    Drugs 69:1239-65. 2009
    ..Losartan/HCTZ is a well tolerated combination therapy. Thus, losartan/HCTZ remains an important option in the treatment of hypertension, as well as being indicated to reduce stroke risk in patients with hypertension and LVH...
  11. doi request reprint Brinzolamide/timolol: in open-angle glaucoma and ocular hypertension
    Jamie D Croxtall
    Wolters Kluwer Health, Adis, Auckland, New Zealand
    Drugs Aging 26:437-46. 2009
    ..Moreover, a significantly greater number of patients expressed a preference for brinzolamide/timolol over dorzolamide/timolol. The main ocular adverse event was blurred vision, and was not considered to be a safety issue...
  12. doi request reprint Argatroban: a review of its use in the management of heparin-induced thrombocytopenia
    Sohita Dhillon
    Wolters Kluwer Health Adis, Auckland, New Zealand
    Am J Cardiovasc Drugs 9:261-82. 2009
    ..However, a small uncontrolled, preliminary study suggests that it may be useful in seriously ill pediatric patients requiring nonheparin anticoagulation...
  13. doi request reprint Alitretinoin: in severe chronic hand eczema
    Karly P Garnock-Jones
    Wolters Kluwer Health Adis, 41 Centorian Drive, Mairangi Bay, North Shore 0754, Auckland, New Zealand
    Drugs 69:1625-34. 2009
    ..The most common treatment-emergent adverse events and abnormal laboratory test results were consistent with those previously observed with other oral retinoids and RXR agonists...
  14. ncbi request reprint Nesiritide: a review of its use in acute decompensated heart failure
    Gillian M Keating
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 63:47-70. 2003
    ..Most episodes of symptomatic hypotension resolved spontaneously or after an intravenous volume challenge of </=250 ml. In addition, nesiritide does not appear to be proarrhythmic...
  15. doi request reprint Pregabalin: in the treatment of postherpetic neuralgia
    Kate McKeage
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs Aging 26:883-92. 2009
    ..Pregabalin was generally well tolerated when titrated over 1 week to fixed dosages (maximum 600 mg/day) in clinical trials in mostly elderly PHN patients. Adverse events were usually mild to moderate in severity...
  16. doi request reprint Everolimus: in advanced renal cell carcinoma
    Karly P Garnock-Jones
    Adis, Auckland, New Zealand
    Drugs 69:2115-24. 2009
    ..The tolerability profile of everolimus was largely manageable in the phase III trial, with most treatment-related adverse events being of grade 1 or 2 severity...
  17. ncbi request reprint Airmax: a multi-dose dry powder inhaler
    Gillian M Keating
    Adis International Limited, Auckland, New Zealand
    Drugs 62:1887-95; discussion 1896-7. 2002
    ..Both adults and children preferred Airmax to Turbuhaler, and more found Airmax easier to use. In one study, the majority of children found learning how to use Airmax trade mark easier than learning how to use Turbuhaler...
  18. ncbi request reprint Pneumococcal conjugate vaccine (Prevnar; PNCRM7): a review of its use in the prevention of Streptococcus pneumoniae infection
    Malcolm J M Darkes
    Adis International Inc, Langhorne, Pennsylvania 19047, USA
    Paediatr Drugs 4:609-30. 2002
    ..influenzae type b vaccines did not affect the immunogenicity of these pediatric vaccines to a clinically relevant extent...
  19. doi request reprint Trabectedin: a review of its use in soft tissue sarcoma and ovarian cancer
    Natalie J Carter
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs 70:355-76. 2010
    ....
  20. ncbi request reprint Perindopril: in congestive heart failure
    Dene Simpson
    Adis International Limited, Auckland, New Zealand
    Drugs 62:1367-77; discussion 1378-9. 2002
    ....
  21. doi request reprint Histrelin: in advanced prostate cancer
    Emma D Deeks
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs 70:623-30. 2010
    ..No patients prematurely discontinued treatment because of adverse events, most of which were the consequence of hormone suppression...
  22. doi request reprint Bivalirudin: in patients with ST-segment elevation myocardial infarction
    Monique P Curran
    Adis, Wolters Kluwer Business, Auckland, New Zealand
    Drugs 70:909-18. 2010
    ....
  23. ncbi request reprint Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed) [Cervarix]: profile report
    Susan J Keam
    Wolters Kluwer Health Adis, Auckland, New Zealand
    BioDrugs 22:205-8. 2008
  24. ncbi request reprint Bemiparin: a review of its use in the prevention of venous thromboembolism and treatment of deep vein thrombosis
    Therese M Chapman
    Adis International Limited, Auckland, New Zealand
    Drugs 63:2357-77. 2003
    ..The most commonly reported adverse events in clinical trials were postoperative bleeding complications (similar incidence to that with UFH or enoxaparin in high-risk patients, lower incidence in low- to moderate-risk patients)...
  25. ncbi request reprint Intranasal sumatriptan: in adolescents with migraine
    Monique P Curran
    Adis International Limited, Auckland, New Zealand
    CNS Drugs 19:335-43; discussion 345-6. 2005
    ..Taste disturbance occurred more often with intranasal sumatriptan than with placebo [Chart: see text]...
  26. ncbi request reprint Zonisamide: a review of its use in the management of partial seizures in epilepsy
    James E Frampton
    Adis International Limited, Auckland, New Zealand
    CNS Drugs 19:347-67. 2005
    ..In the meantime, adjunctive therapy or monotherapy with zonisamide is a convenient, useful option for the management of partial seizures, including those refractory to other AEDs...
  27. ncbi request reprint Lansoprazole: in the treatment of gastro-oesophageal reflux disease in children and adolescents
    Katherine F Croom
    Adis International Limited, Auckland, New Zealand
    Drugs 65:2129-35; discussion 2136-7. 2005
    ..Lansoprazole was generally well tolerated in children and adolescents, with the most common treatment-related adverse events being gastrointestinal events and headache...
  28. ncbi request reprint Solifenacin in overactive bladder syndrome
    Dene Simpson
    Adis International Limited, Auckland, New Zealand
    Drugs Aging 22:1061-9. 2005
    ..Solifenacin was generally well tolerated; the most frequently reported adverse events were dry mouth, constipation and blurred vision...
  29. ncbi request reprint Darifenacin: in the treatment of overactive bladder
    Katherine F Croom
    Adis International Limited, Auckland, New Zealand
    Drugs Aging 21:885-92; discussion 893-4. 2004
    ..The most common adverse events were dry mouth and constipation. CNS tolerability appeared to be similar to that of placebo. Darifenacin had no adverse effect on cognitive function in healthy elderly volunteers...
  30. ncbi request reprint Modified-release nifedipine: a review of the use of modified-release formulations in the treatment of hypertension and angina pectoris
    Katherine F Croom
    Adis International Limited, Auckland, New Zealand
    Drugs 66:497-528. 2006
    ....
  31. ncbi request reprint Insulin aspart: a review of its use in the management of type 1 or 2 diabetes mellitus
    Neil A Reynolds
    Adis International Limited, Auckland, New Zealand
    Drugs 64:1957-74. 2004
    ..Insulin aspart is an effective and well tolerated alternative to regular human insulin and insulin lispro for the maintenance of glycaemic control in patients with type 1 or 2 diabetes...
  32. ncbi request reprint Gadofosveset
    Sheridan Henness
    Adis International Limited, 41 Centorian Drive, Mairangi Bay, Auckland 1311, New Zealand
    Drugs 66:851-7. 2006
    ..Gadofosveset was generally well tolerated in clinical trials, with most adverse events being mild or moderate in severity...
  33. ncbi request reprint Clopidogrel: a pharmacoeconomic review of its use in patients with non-ST elevation acute coronary syndromes
    Katherine A Lyseng-Williamson
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Pharmacoeconomics 24:709-26. 2006
    ..Available pharmacoeconomic data from several countries, despite some inherent limitations, support the use of clopidogrel plus aspirin for up to 1 year as a cost-effective treatment relative to aspirin alone in this patient population...
  34. ncbi request reprint Intravenous ibandronate: in the treatment of osteoporosis
    Katherine F Croom
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 66:1593-601; discussion 1602-3. 2006
    ..IV ibandronate was generally well tolerated in clinical trials. Treatment-related adverse events included musculoskeletal events and transient influenza-like symptoms, the latter mainly associated with the first dose...
  35. ncbi request reprint Orlistat: a review of its use in the management of obesity
    Sheridan Henness
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 66:1625-56. 2006
    ..Thus, orlistat is an option for the treatment of obese patients with or without type 2 diabetes and also has a role in the management of obese patients with the metabolic syndrome, associated comorbidities or concomitant disorders...
  36. ncbi request reprint Ximelagatran/Melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery
    Hannah C Evans
    Adis International Limited, 41 Centorian Drive, PB 65901, Mairangi Bay, Auckland 1311, New Zealand
    Drugs 64:649-78. 2004
    ..In a post-hoc analysis of one study, transfusion rates were lower in ximelagatran than enoxaparin recipients...
  37. ncbi request reprint Epoetin Beta: a review of its clinical use in the treatment of anaemia in patients with cancer
    Susan M Cheer
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 64:323-46. 2004
    ..In general, the efficacy of epoetin beta is not limited by tumour type. Response to the drug occurred irrespective of the nature (platinum- or nonplatinum-based) or presence of chemotherapy treatment in randomised trials...
  38. ncbi request reprint Cetuximab: in the treatment of metastatic colorectal cancer
    Neil A Reynolds
    Adis International Limited, Mairangi Bay, Auckland 1311, New Zealand
    Drugs 64:109-18; discussion 119-121. 2004
    ..In patients receiving cetuximab plus irinotecan, these were diarrhoea, asthenia, leucopenia and neutropenia...
  39. ncbi request reprint Zoledronic acid : a review of its use in the management of bone metastases of malignancy
    Sohita Dhillon
    Wolters Kluwer Health Adis, Auckland, New Zealand
    Drugs 68:507-34. 2008
    ..Nevertheless, available clinical data indicate that zoledronic acid is an effective treatment option for the management of bone metastases of malignancy...
  40. ncbi request reprint Mosapride in gastrointestinal disorders
    Monique P Curran
    Wolters Kluwer Health, Adis, Auckland, New Zealand
    Drugs 68:981-91. 2008
    ..Mosapride was well tolerated, with diarrhoea/loose stools, dry mouth, malaise and headache being reported in <5% of patients...
  41. doi request reprint Mifamurtide: a review of its use in the treatment of osteosarcoma
    James E Frampton
    Adis, a Wolters Kluwer Business, Mairangi Bay, North Shore, Auckland, New Zealand
    Paediatr Drugs 12:141-53. 2010
    ..Based on the available data, mifamurtide can be considered for inclusion in treatment protocols for localized osteosarcoma...
  42. ncbi request reprint Olanzapine: a review of its use in the treatment of bipolar I disorder
    N Bhana
    Adis International Limited, Auckland, New Zealand
    CNS Drugs 15:871-904. 2001
    ..Olanzapine was generally well tolerated with no clinically relevant abnormalities in laboratory tests, vital signs or electrocardiogram results...
  43. ncbi request reprint Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria
    K Simpson
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 59:301-21. 2000
    ..As it does not cross the blood brain barrier, fexofenadine is free of the sedative effects associated with first generation antihistamines, even at dosages of up to 240 mg/day...
  44. ncbi request reprint Docetaxel: an update of its use in advanced breast cancer
    D P Figgitt
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 59:621-51. 2000
    ..The role of docetaxel in the adjuvant and neoadjuvant treatment of early breast cancer is being evaluated...
  45. ncbi request reprint Linezolid
    D Clemett
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 59:815-27; discussion 828. 2000
    ..Linezolid is generally well tolerated and gastrointestinal disturbances are the most commonly occurring adverse events. No clinical evidence of adverse reactions as a result of monoamine oxidase inhibition has been reported...
  46. ncbi request reprint Ropinirole: a review of its use in the management of Parkinson's disease
    A J Matheson
    Adis International Limited, Auckland, New Zealand
    Drugs 60:115-37. 2000
    ..Prior to the addition of supplementary levodopa 5% of ropinirole recipients had experienced dyskinesia compared with 36% of those receiving levodopa...
  47. doi request reprint Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma
    Gillian M Keating
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs 71:1623-47. 2011
    ..In conclusion, plerixafor is a valuable stem-cell mobilizer for use in combination with G-CSF in patients with lymphoma or MM, particularly in patients who are poor mobilizers or predicted poor mobilizers...
  48. doi request reprint Denosumab: in cancer treatment-induced bone loss
    Victoria J Muir
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    BioDrugs 24:379-86. 2010
    ..Denosumab treatment was generally well tolerated for up to 24 months in breast cancer patients and for up to 36 months in prostate cancer patients...
  49. doi request reprint Tdap5 vaccine (Covaxis): a review of its use as a single-booster immunization for the prevention of tetanus, diphtheria, and pertussis in children (aged 4 years), adolescents, and adults
    Lesley J Scott
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    BioDrugs 24:387-406. 2010
    ....
  50. ncbi request reprint Budesonide inhalation suspension: a review of its use in infants, children and adults with inflammatory respiratory disorders
    K M Hvizdos
    Adis International Limited, Auckland, New Zealand
    Drugs 60:1141-78. 2000
    ..The preparation is suitable for use in infants, children and adults with persistent asthma and in infants and children with croup...
  51. doi request reprint Spinosad: in pediculosis capitis
    Paul L McCormack
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Am J Clin Dermatol 12:349-53. 2011
    ..Spinosad was generally well tolerated in clinical trials, with no severe or serious adverse events. Cutaneous and ocular irritation were the most common adverse events...
  52. ncbi request reprint Topical dorzolamide 2%/timolol 0.5%: a review of its use in the treatment of open-angle glaucoma
    D Ormrod
    Adis International Limited, Auckland, New Zealand
    Drugs Aging 17:477-96. 2000
    ..Furthermore, dorzolamide is a sulfonamide and can cause allergic reactions in those who are hypersensitive to this class of drug...
  53. ncbi request reprint Linezolid: a review of its use in the management of serious gram-positive infections
    C M Perry
    Adis International Limited, Auckland, New Zealand
    Drugs 61:525-51. 2001
    ..The most frequently reported adverse events in linezolid recipients were diarrhoea, headache, nausea and vomiting. Thrombocytopenia was also documented in a small proportion (about 2%) of patients treated with the drug...
  54. ncbi request reprint Topical aminolevulinic acid HCl photodynamic therapy
    D Ormrod
    Adis International Limited, Auckland, New Zealand
    Am J Clin Dermatol 1:133-9; discussion 140-1. 2000
    ..Localized erythema and edema were also common. No other significant adverse effects were noted and treatment was generally well tolerated. A well designed dermal applicator ensured perilesional skin was spared collateral damage...
  55. ncbi request reprint Darbepoetin alfa
    T Ibbotson
    Adis International Limited, Auckland, New Zealand
    Drugs 61:2097-104; discussion 2105-6. 2001
    ..There have been no reports of immune responses to darbepoetin alfa in 1534 patients receiving treatment for up to 2 years...
  56. ncbi request reprint Bexarotene
    M N Lowe
    Adis International Limited, Auckland, New Zealand
    Am J Clin Dermatol 1:245-50; discussion 251-2. 2000
    ..Reversible acute pancreatitis has occurred during oral bexarotene therapy. Adverse events associated with the topical formulation are limited to rash, pruritus, and pain...
  57. doi request reprint Eltrombopag: a review of its use in treatment-refractory chronic primary immune thrombocytopenia
    Karly P Garnock-Jones
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs 71:1333-53. 2011
    ..Eltrombopag is an effective treatment option for adult patients with chronic ITP and an increased risk of bleeding who are refractory to previous treatments, including splenectomy, as demonstrated in well designed clinical trials...
  58. doi request reprint Pharmacoeconomic spotlight on varenicline as an aid to smoking cessation
    Gillian M Keating
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    CNS Drugs 24:797-800. 2010
    ....
  59. ncbi request reprint Drotrecogin alfa (activated)
    Katherine A Lyseng-Williamson
    Adis International Limited, Auckland, New Zealand
    Drugs 62:617-30; discussion 631-2. 2002
    ..Of the 210 deaths in patients with severe sepsis treated with drotrecogin alfa (activated) 24 microg/kg/h in the efficacy trial, four deaths due to haemorrhage and one due to cerebral oedema were possibly related to the study drug...
  60. doi request reprint DTPa-HBV-IPV/Hib Vaccine (Infanrix hexa): A Review of its Use as Primary and Booster Vaccination
    Sohita Dhillon
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs 70:1021-58. 2010
    ....
  61. ncbi request reprint Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders
    A J Wagstaff
    Adis International Limited, Auckland, New Zealand
    Drugs 53:435-52. 1997
    ..Tizanidine, therefore, appears to be an attractive therapeutic alternative for patients with spasticity associated with cerebral or spinal damage...
  62. ncbi request reprint Topical pimecrolimus: a review of its clinical potential in the management of atopic dermatitis
    Keri Wellington
    Adis International Limited, Auckland, New Zealand
    Drugs 62:817-40. 2002
    ..Pimecrolimus 1.0% cream provides a promising and well tolerated treatment option in the management of infants, children and adults with mild to moderate atopic dermatitis...
  63. ncbi request reprint Mirtazapine: a review of its use in major depression
    K J Holm
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 57:607-31. 1999
    ..In vitro and in vivo data have suggested that mirtazapine is unlikely to affect the metabolism of drugs metabolised by cytochrome P450 (CYP)2D6, although few formal drug interaction data are available...
  64. ncbi request reprint Pramipexole. A review of its use in the management of early and advanced Parkinson's disease
    M Dooley
    Adis International Limited, Auckland, New Zealand
    Drugs Aging 12:495-514. 1998
    ..The incidence of some adverse events did not greatly differ between pramipexole and placebo recipients...
  65. ncbi request reprint Fenoldopam: a review of its pharmacodynamic and pharmacokinetic properties and intravenous clinical potential in the management of hypertensive urgencies and emergencies
    R N Brogden
    Adis International Limited, Auckland, New Zealand
    Drugs 54:634-50. 1997
    ..Fenoldopam may be particularly useful in patients who develop hypertension after coronary artery bypass graft surgery, but further studies are required to confirm its role in hypertensive emergency...
  66. doi request reprint Intanza 15 microg intradermal seasonal influenza vaccine: in older adults (aged >or=60 years)
    Sean T Duggan
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs Aging 27:597-605. 2010
    ....
  67. ncbi request reprint Donepezil
    H M Bryson
    Adis International Limited, Auckland, New Zealand
    Drugs Aging 10:234-9; discussion 240-1. 1997
    ..No hepatotoxicity was reported after 12 weeks' treatment...
  68. doi request reprint Trastuzumab: in HER2-positive metastatic gastric cancer
    Jamie D Croxtall
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs 70:2259-67. 2010
    ..In general, combination therapy with trastuzumab and chemotherapy was relatively well tolerated in patients with metastatic gastric cancer with no reports of new or unexpected adverse events...
  69. ncbi request reprint Telmisartan: a review of its use in the management of hypertension
    Anna J Battershill
    Adis International Limited, Auckland, New Zealand
    Drugs 66:51-83. 2006
    ....
  70. ncbi request reprint Everolimus
    Therese M Chapman
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 64:861-72; discussion 873-4. 2004
    ..Everolimus has been associated with thrombocytopenia, leucopenia and elevated serum lipids and creatinine...
  71. ncbi request reprint Adalimumab: a review of its use in rheumatoid arthritis
    Lynne M Bang
    Adis International Inc, 770 Township Line Road, Suite 300, Yardley, PA 19067, USA
    BioDrugs 18:121-39. 2004
    ..The drug also retards the progression of structural joint damage, improves HR-QOL, and is generally well tolerated. Thus, adalimumab is a valuable new option for the treatment of DMARD-refractory adult rheumatoid arthritis...
  72. ncbi request reprint Voriconazole: in the treatment of invasive aspergillosis
    Richard B R Muijsers
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 62:2655-64; discussion 2665-6. 2002
    ..02 both comparisons) fewer treatment-related adverse events or serious adverse events. The incidence of visual disturbances was significantly (p < 0.001) higher with voriconazole than amphotericin B treatment...
  73. ncbi request reprint Pioglitazone: a review of its use in type 2 diabetes mellitus
    John Waugh
    Adis International Limited, Auckland, New Zealand
    Drugs 66:85-109. 2006
    ..Pioglitazone was also effective in reducing some measures of cardiovascular risk and arteriosclerosis. Pioglitazone thus offers an effective treatment option for the management of patients with type 2 diabetes...
  74. doi request reprint Varenicline: a pharmacoeconomic review of its use as an aid to smoking cessation
    Gillian M Keating
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Pharmacoeconomics 28:231-54. 2010
    ....
  75. ncbi request reprint Remifentanil : a review of its analgesic and sedative use in the intensive care unit
    Anna J Battershill
    Adis International Limited, Auckland, New Zealand
    Drugs 66:365-85. 2006
    ..Thus, remifentanil is a welcome addition to the currently available pharmacological agents employed in the management of mechanically ventilated ICU patients...
  76. ncbi request reprint Lansoprazole: in the management of gastroesophageal reflux disease in children
    Lesley J Scott
    Adis International Inc, Langhorne, Pennsylvania 10947, USA
    Paediatr Drugs 5:57-61; discussion 62. 2003
    ..The drug is generally well tolerated in children with GERD. In the largest study, the most common treatment-related adverse events occurring during therapy were constipation and headache...
  77. ncbi request reprint Fixed combination trandolapril/verapamil sustained-release: a review of its use in essential hypertension
    Richard B R Muijsers
    Adis International Limited, Auckland, New Zealand
    Drugs 62:2539-67. 2002
    ..Data from large clinical trials currently being conducted will assist in fully defining the role of trandolapril/verapamil SR as a cardio- and renoprotective agent...
  78. ncbi request reprint Clarithromycin extended-release tablet: a review of its use in the management of respiratory tract infections
    Malcolm J M Darkes
    Adis International Inc, Langhorne, Pennsylvania, USA
    Am J Respir Med 2:175-201. 2003
    ..Further studies are required to assess the cost-effectiveness ratio of clarithromycin relative to comparator antibacterial agents...
  79. ncbi request reprint Glucosamine: a review of its use in the management of osteoarthritis
    Anna J Matheson
    Adis International Limited, Auckland, New Zealand
    Drugs Aging 20:1041-60. 2003
    ..In general, a lower incidence of withdrawal from clinical trials was reported for glucosamine recipients than either ibuprofen or piroxicam recipients...
  80. ncbi request reprint Micafungin
    Blair Jarvis
    Adis International Limited, 41 Centorial Drive, Mairangi Bay, Auckland 1311, New Zealand
    Drugs 64:969-82; discussion 983-4. 2004
    ..5-900 mg/day; no histamine-like reactions occurred. Micafungin was as well tolerated as fluconazole, with numerically fewer micafungin recipients discontinuing treatment (4.2% vs 7.2%)...
  81. ncbi request reprint Reteplase: a review of its use in the management of thrombotic occlusive disorders
    Dene Simpson
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Am J Cardiovasc Drugs 6:265-85. 2006
    ....
  82. doi request reprint Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis
    Vicki Oldfield
    Wolters Kluwer Health Adis, North Shore, Auckland, New Zealand
    BioDrugs 23:125-35. 2009
    ..The tolerability profile of golimumab was generally consistent with that of other anti-TNF agents...
  83. ncbi request reprint Mycophenolate mofetil: a pharmacoeconomic review of its use in solid organ transplantation
    Melissa Young
    Adis International Ltd, Auckland, New Zealand
    Pharmacoeconomics 20:675-713. 2002
    ..Additional pharmacoeconomic analyses of mycophenolate mofetil are also needed in other types of solid organ transplantation...
  84. ncbi request reprint Goserelin: a review of its use in the treatment of early breast cancer in premenopausal and perimenopausal women
    Susan M Cheer
    Adis International Limited, Auckland, New Zealand
    Drugs 65:2639-55. 2005
    ....
  85. ncbi request reprint Triflusal: a review of its use in cerebral infarction and myocardial infarction, and as thromboprophylaxis in atrial fibrillation
    David Murdoch
    Adis International Limited, Auckland, New Zealand
    Drugs 66:671-92. 2006
    ....
  86. ncbi request reprint Insulin lispro: a pharmacoeconomic review of its use in diabetes mellitus
    Christopher J Dunn
    Adis International Limited, Auckland, New Zealand
    Pharmacoeconomics 20:989-1025. 2002
    ....
  87. ncbi request reprint Amisulpride: a review of its use in the management of schizophrenia
    Kate McKeage
    Adis International Limited, Auckland, New Zealand
    CNS Drugs 18:933-56. 2004
    ..Thus, amisulpride is an effective and well tolerated option for the first-line treatment of patients with acute schizophrenia as well as for those requiring long-term maintenance therapy...
  88. ncbi request reprint Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder
    Nishan S Gunasekara
    Adis International Limited, Auckland, New Zealand
    Drugs 62:1217-51. 2002
    ..In addition, intramuscular ziprasidone reduced agitation scores by a significantly greater extent than haloperidol in a study involving patients with acute agitation associated with psychosis...
  89. ncbi request reprint Inhaled salmeterol/fluticasone propionate combination in chronic obstructive pulmonary disease
    Katherine A Lyseng-Williamson
    Adis International Inc, Langhorne, Pennsylvania 19047, USA
    Am J Respir Med 1:273-82; discussion 283-4. 2002
    ..Candidiasis, hoarseness/dysphonia, throat irritation and headache occurred more frequently with salmeterol/fluticasone propionate than with placebo in patients with COPD...
  90. ncbi request reprint Tipranavir: a review of its use in the management of HIV infection
    Jennifer S Orman
    Wolters Kluwer Health Adis, Auckland, New Zealand
    Drugs 68:1435-63. 2008
    ..Thus, tipranavir, administered with ritonavir, is an effective treatment option for use in the combination therapy of adults with HIV-1 infection who have been previously treated with other antiretroviral drugs...
  91. ncbi request reprint Atomoxetine
    Dene Simpson
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Paediatr Drugs 5:407-15; discussion 416-7. 2003
    ..The most common treatment-related adverse event was decreased appetite. Atomoxetine shows no abuse potential and is not a controlled substance in the US...
  92. doi request reprint Risedronate on two consecutive days per month
    James E Frampton
    Wolters Kluwer Health, Adis, Auckland, New Zealand
    Drugs Aging 26:355-62. 2009
    ..The tolerability profile (including the incidence of upper gastrointestinal tract adverse events) of risedronate 75 mg 2CDM in postmenopausal women with osteoporosis was similar to that of risedronate 5 mg once daily...
  93. ncbi request reprint Pregabalin: in the treatment of generalised anxiety disorder
    James E Frampton
    Adis International Limited, Auckland, New Zealand
    CNS Drugs 20:685-93; discussion 694-5. 2006
    ..black triangle The drug was not associated with a clinically significant medication withdrawal syndrome during a 1-week taper following 4 or 6 weeks' double-blind treatment...
  94. ncbi request reprint Efavirenz/emtricitabine/tenofovir disoproxil fumarate: triple combination tablet
    James E Frampton
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 66:1501-12; discussion 1513-4. 2006
    ..CNS adverse events, primarily headache and dizziness, were the most common treatment-emergent, drug-related adverse events in the pharmacokinetic study involving the co-formulation...
  95. ncbi request reprint Drotrecogin alfa (activated): a pharmacoeconomic review of its use in severe sepsis
    James E Frampton
    Adis International Limited, Auckland, New Zealand
    Pharmacoeconomics 22:445-76. 2004
    ..g APACHE II score of > or =25 and/or > or = 2 OSFs), has a lifetime cost-effectiveness profile that compares well to that of many widely accepted therapies...
  96. ncbi request reprint Emtricitabine: a review of its use in the management of HIV infection
    James E Frampton
    Adis International Limited, Auckland, New Zealand
    Drugs 65:1427-48. 2005
    ..Similarly, emtricitabine is attractive as an option for ART-experienced stable adults requiring regimen simplification...
  97. doi request reprint Lapatinib: a review of its use in the treatment of HER2-overexpressing, trastuzumab-refractory, advanced or metastatic breast cancer
    James E Frampton
    Adis, Auckland, New Zealand
    Drugs 69:2125-48. 2009
    ..Lapatinib combined with capecitabine provides an effective therapeutic option for a group of patients who currently have few treatment choices...
  98. ncbi request reprint Reduced-antigen, combined diphtheria, tetanus, and acellular pertussis vaccine (Boostrix): a review of its use as a single-dose booster immunization
    James E Frampton
    Wolters Kluwer Health, Adis, Auckland, New Zealand
    BioDrugs 20:371-89. 2006
    ....
  99. ncbi request reprint Topical brimonidine 0.2%/timolol 0.5% ophthalmic solution: in glaucoma and ocular hypertension
    James E Frampton
    Wolters Kluwer Health, Adis, Auckland, New Zealand
    Drugs Aging 23:753-61. 2006
    ..Brimonidine/timolol may be advantageous over dorzolamide/timolol with respect to ocular tolerability and comfort (preliminary data)...
  100. ncbi request reprint Hexyl aminolevulinate in the detection of bladder cancer: profile report
    James E Frampton
    Wolters Kluwer Health, Adis, 41 Centorian Drive, Mairangi Bay, Auckland 1311, New Zealand
    BioDrugs 20:317-20. 2006
  101. ncbi request reprint Topical dorzolamide 2%/timolol 0.5% ophthalmic solution: a review of its use in the treatment of glaucoma and ocular hypertension
    James E Frampton
    Wolters Kluwer Health Adis, Auckland, New Zealand
    Drugs Aging 23:977-95. 2006
    ..Compared with concomitant therapy with the individual components, the primary advantage of fixed combination dorzolamide/timolol is convenience...